REVIEW ARTIKEL: PENGARUH METFORMIN SEBAGAI OBAT OFF-LABEL UNTUK TERAPI PADA WANITA DENGAN POLYCYSTIC OVARY SYNDROME

Christine - Christine, Eli - Halimah, David Christianto Yohanes

Abstrak


Salah satu penyebab infertilitas pada wanita disebabkan oleh PCOS yang mempengaruhi anovulasi menstruasi dengan gejala klinis berupa hiperandrogenemia, gangguan menstruasi, jerawat berlebih serta hirsutisme. PCOS juga ditandai dengan morfologi ovarium polikistik, infertilitas anovulasi,  gangguan metabolisme seperti obesitas, serta peningkatan kadar androgen dalam darah. Beberapa obat telah digunakan untuk pengobatan gejala klinis dari PCOS termasuk obat off-label yang sering digunakan sebagai terapi selain indikasi yang telah disetujui oleh FDA (Food and Drug Administation). Metformin merupakan salah satu obat off-label yang digunakan untuk pengobatan PCOS dengan indikasi untuk menginduksi ovulasi, mengatur regulasi menstruasi, penurunan berat badan, serta hirsutisme. Metode penulisan artikel ini menggunakan kajian naratif dengan menggunakan database PUBMED dengan kata kunci Metformin Effect dan PCOS.  Beberapa hasil penelitian menunjukkan bahwa metformin memiliki pengaruh yang signifikan terhadap penurunan berat badan, hiperandrogenisme, hirsutisme dan jerawat, perbaikan terhadap siklus menstruasi, tingkat kehamilan meningkat, penurunan volume ovarium, serta peningkatan induksi ovulasi pada wanita infertilitas yang mengidap PCOS dalam rentang dosis yang diberikan 500 – 2550 mg setiap harinya.


Teks Lengkap:

PDF

Referensi


Abd Elgafor, I. (2013). Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. Archives of Gynecology and Obstetrics, 288(1), 119–123. https://doi.org/10.1007/s00404-013-2714-2

Agrawal, A., Mahey, R., Kachhawa, G., Khadgawat, R., Vanamail, P., & Kriplani, A. (2019). Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecological Endocrinology, 35(6), 511–514. https://doi.org/10.1080/09513590.2018.1549656

Ali, D. E. S., Shah, M., Ali, A., Malik, M. O., Rehman, F., Badshah, H., Ehtesham, E., & Vitale, S. G. (2019). Treatment with Metformin and Combination of Metformin plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial. Hormone and Metabolic Research, 51(11), 714–722. https://doi.org/10.1055/a-1018-9606

Altinok, M. L., Ravn, P., Andersen, M., & Glintborg, D. (2018). Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. Gynecological Endocrinology, 34(10), 859–863. https://doi.org/10.1080/09513590.2018.1460343

Al-Zubeidi, H., & Klein, K. O. (2015). Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism, 28(7–8), 853–858. https://doi.org/10.1515/jpem-2014-0283

Andræ, F., Abbott, D., Stridsklev, S., Schmedes, A. V., Odsæter, I. H., Vanky, E., & Salvesen, Ø. (2020). Sustained Maternal Hyperandrogenism during PCOS Pregnancy Reduced by Metformin in Non-Obese Women Carrying a Male Foetus. Journal of Clinical Endocrinology and Metabolism, 105(12), 3762–3770.

Aziza, D. octaviana, & Kurniati, K. I. (2019). Suplementasi Vitamin D pada Wanita dengan Polycystic Ovarian Syndrome (PCOS). Jurnal Ilmiah Kesehatan Sandi Husada, 8(2), 169–177. https://doi.org/10.35816/jiskh.v8i2.140

Badan Pusat Statistik. (2013). Riset Kesehatan Dasar. In Science (Vol. 127, Issue 3309). https://doi.org/10.1126/science.127.3309.1275

Bordewijk, E. M., Nahuis, M., Costello, M. F., Van der Veen, F., Tso, L. O., Mol, B. W. J., & van Wely, M. (2017). Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2017(1). https://doi.org/10.1002/14651858.CD009090.pub2

Curi, D. D. G., Fonseca, A. M., Marcondes, J. A. M., Almeida, J. A. M., Bagnoli, V. R., Soares, J. M., & Baracat, E. C. (2012). Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecological Endocrinology, 28(3), 182–185. https://doi.org/10.3109/09513590.2011.583957

Deswal, R., Narwal, V., Dang, A., & Pundir, C. S. (2020). The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. Journal of Human Reproductive Sciences, 13(4), 261–271. https://doi.org/10.4103/jhrs.JHRS_95_18

Dumitrescu, R., Mehedintu, C., Briceag, I., Purcărea, V. L., & Hudita, D. (2015). Metformin-clinical pharmacology in PCOs. Journal of Medicine and Life, 8(2), 187–192.

El Sharkwy, I., & Sharaf El-Din, M. (2019). l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. Gynecological Endocrinology, 35(8), 701–705. https://doi.org/10.1080/09513590.2019.1576622

Elkind-Hirsch, K. E., Paterson, M. S., Seidemann, E. L., & Gutowski, H. C. (2017). Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot . Fertility and Sterility, 107(1), 253-260.e1. https://doi.org/10.1016/j.fertnstert.2016.09.023

Figurová, J., Dravecká, I., Petríková, J., Javorský, M., & Lazúrová, I. (2017). The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. Hormone Molecular Biology and Clinical Investigation, 29(3), 85–91. https://doi.org/10.1515/hmbci-2016-0039

Franks, S. (2018). Polycystic ovary syndrome. In Encyclopedia of Endocrine Diseases (2nd ed., Issue February). Elsevier Inc. https://doi.org/10.1016/B978-0-12-801238-3.03910-6

Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017). Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 33(1), 39–42. https://doi.org/10.1080/09513590.2016.1236078

Ganie, M. A., Khurana, M. L., Nisar, S., Shah, P. A., Shah, Z. A., Kulshrestha, B., Gupta, N., Zargar, M. A., Wani, T. A., Mudasir, S., Mir, F. A., & Taing, S. (2013). Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): A six-month, open-label randomized study. Journal of Clinical Endocrinology and Metabolism, 98(9), 3599–3607. https://doi.org/10.1210/jc.2013-1040

Garzia, E., Galiano, V., Marfia, G., Navone, S., Grossi, E., & Marconi, A. M. (2022). Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reproductive Biology and Endocrinology, 20(1), 1–12. https://doi.org/10.1186/s12958-021-00876-0

Glueck, C. J., Goldenberg, N., Pranikoff, J., Khan, Z., Padda, J., & Wang, P. (2013). Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. Current Medical Research and Opinion, 29(1), 55–62. https://doi.org/10.1185/03007995.2012.755121

Grigoryan, O., Absatarova, J., Andreeva, E., Melnichenko, G., & Dedov, I. (2014). Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecology, 66(1), 85–89.

Hirsch, A., Hahn, D., Kempná, P., Hofer, G., Nuoffer, J. M., Mullis, P. E., & Flück, C. E. (2012). Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology, 153(9), 4354–4366. https://doi.org/10.1210/en.2012-1145

Isik, S., Ozcan, H. N., Ozuguz, U., Berker, D., Tutuncu, Y., Akbaba, G., & Guler, S. (2012). Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome. Clinical Endocrinology, 76(3), 373–378. https://doi.org/10.1111/j.1365-2265.2011.04210.x

Kalra, B., Kalra, S., & Sharma, J. B. (2016). The inositols and polycystic ovary syndrome. Indian Journal of Endocrinology and Metabolism, 20(5), 720–724. https://doi.org/10.4103/2230-8210.189231

Kurzthaler, D., Hadziomerovic-Pekic, D., Wildt, L., & Seeber, B. E. (2014). Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects. Reproductive Biology and Endocrinology, 12(1), 1–6. https://doi.org/10.1186/1477-7827-12-98

Li, Y., Tan, J., Wang, Q., Duan, C., Hu, Y., & Huang, W. (2020). Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility, 113(1), 197–204. https://doi.org/10.1016/j.fertnstert.2019.09.011

Løvvik, T. S., Stridsklev, S., Carlsen, S. M., Salvesen, Ø., & Vanky, E. (2016). Cervical length and androgens in pregnant women with polycystic ovary syndrome: Has metformin any effect? Journal of Clinical Endocrinology and Metabolism, 101(6), 2325–2331. https://doi.org/10.1210/jc.2015-3498

Ma, R. L., Deng, Y., Wang, Y. F., Zhu, S. Y., Ding, X. S., & Sun, A. J. (2021). Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese Medical Journal, 134(23), 2882–2889. https://doi.org/10.1097/CM9.0000000000001712

Madsen, H. N., Lauszus, F. F., Trolle, B., Ingerslev, H. J., & Tørring, N. (2015). Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: A secondary analysis of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica, 94(5), 547–551. https://doi.org/10.1111/aogs.12605

Mareta, R., Amran, R., & Larasati, V. (2018). Hubungan Polycystic Ovary Syndrome (PCOS) dengan Infertilitas di Praktik Swasta Dokter Obstetri Ginekologi Palembang. Majalah Kedokteran Sriwijaya, 50(2), 85–91. https://ejournal.unsri.ac.id/index.php/mks/article/view/8552

Mazza, A., Fruci, B., Guzzi, P., D’Orrico, B., Malaguarnera, R., Veltri, P., Fava, A., & Belfiore, A. (2014). In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutrition, Metabolism and Cardiovascular Diseases, 24(2), 132–139. https://doi.org/10.1016/j.numecd.2013.04.016

Mhao, N. S., Al-Hilli, A. S. A., Hadi, N. R., Jamil, D. A., & Al-Aubaidy, H. A. (2016). A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 10(1), S95–S98. https://doi.org/10.1016/j.dsx.2015.10.001

Mohiyiddeen, L., Watson, A. J., Apostolopoulos, N. V., Berry, R., Alexandraki, K. I., & Jude, E. B. (2013). Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 33(2), 165–170. https://doi.org/10.3109/01443615.2012.745839

Nemati, M., Nemati, S., Taheri, A. M., & Heidari, B. (2017). Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. Journal of Gynecology Obstetrics and Human Reproduction, 46(7), 579–585. https://doi.org/10.1016/j.jogoh.2017.07.004

Pau, C. T., Keefe, C., Duran, J., & Welt, C. K. (2014). Metformin improves glucose effectiveness, not insulin sensitivity: Predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. Journal of Clinical Endocrinology and Metabolism, 99(5), 1870–1878. https://doi.org/10.1210/jc.2013-4021

Poli Mara Spritzer, Carolina Rocha Barone, & Fabiana Bazanella de Oliveria. (2016). Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management. Curr Pharm Ces, 22(36), 5603–5613. https://pubmed.ncbi.nlm.nih.gov/27510481/

Pourghasem, S., Bazarganipour, F., Taghavi, S. A., & Kutenaee, M. A. (2019). The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Archives of Gynecology and Obstetrics, 0123456789, 1–7. https://doi.org/10.1007/s00404-019-05064-5

Prabhakar, P., Mahey, R., Gupta, M., Khadgawat, R., Kachhawa, G., Sharma, J. B., Vanamail, P., Kumari, R., & Bhatla, N. (2021). Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial. Gynecological Endocrinology, 37(4), 332–336. https://doi.org/10.1080/09513590.2020.1810657

Pradas, I., Rovira-Llopis, S., Naudí, A., Bañuls, C., Rocha, M., Hernandez-Mijares, A., Pamplona, R., Victor, V. M., & Jové, M. (2019). Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women. Scientific Reports, 9(1), 1–11. https://doi.org/10.1038/s41598-019-52263-w

Ruan, X., Song, J., Gu, M., Wang, L., Wang, H., & Mueck, A. O. (2018). Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics, 297(6), 1557–1563. https://doi.org/10.1007/s00404-018-4762-0

Sahu, A., Tripathy, P., Mohanty, J., & Nagy, A. (2019). Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. Journal of Gynecology Obstetrics and Human Reproduction, 48(5), 335–339. https://doi.org/10.1016/j.jogoh.2018.10.006

Seyam, E., & Hefzy, E. (2018). Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological Endocrinology, 34(12), 1073–1080. https://doi.org/10.1080/09513590.2018.1490405

Stepto, N. K., Cassar, S., Joham, A. E., Hutchison, S. K., Harrison, C. L., Goldstein, R. F., & Teede, H. J. (2013). Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction, 28(3), 777–784. https://doi.org/10.1093/humrep/des463

Tagliaferri, V., Romualdi, D., Immediata, V., Cicco, S. De, Florio, C. Di, Lanzone, A., Guido, M., & Tosetto, A. (2016). Metformin versus myoinositol: which is better in obese PCOS patients? A randomized controlled crossover study. Clinical Endocrinology, 86(5), 725–730. https://doi.org/10.1111/ijlh.12426

Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2010). Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews, 5. https://doi.org/10.1002/14651858.cd003053.pub4

Tejpal, C., Poudel, I., & Jahan, N. (2019). Is Metformin the Answer for Distressed Females with Menstrual Irregularities? Cureus, 11(8). https://doi.org/10.7759/cureus.5460

Vitek, W., Alur, S., & Hoeger, K. M. (2015). Off-label drug use in the treatment of polycystic ovary syndrome. Fertility and Sterility, 103(3), 605–611. https://doi.org/10.1016/j.fertnstert.2015.01.019

Yang, P. K., Hsu, C. Y., Chen, M. J., Lai, M. Y., Li, Z. R., Chen, C. H., Chen, S. U., & Ho, H. N. (2018). The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 103(3), 890–899. https://doi.org/10.1210/jc.2017-01739

Zahra, M., Shah, M., Ali, A., & Rahim, R. (2017). Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome. Hormone and Metabolic Research, 49(2), 103–108. https://doi.org/10.1055/s-0042-119041




DOI: https://doi.org/10.24198/farmaka.v21i1.44306

DOI (PDF): https://doi.org/10.24198/farmaka.v21i1.44306.g19753

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved